CHARLA FONTAINE: Open Payments
NPI 1376621201 · MISSOULA, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,485 in 80 payments from 15 companies in 2025. Trend: 2023 $848 · 2024 $1,393 · 2025 $1,485
Food & beverage: $1,485
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $369 |
| UCB, Inc. | 8 | $178 |
| Lilly USA, LLC | 10 | $174 |
| Novartis Pharmaceuticals Corporation | 8 | $167 |
| Regeneron Healthcare Solutions, Inc. | 6 | $154 |
| GENZYME CORPORATION | 5 | $114 |
| Incyte Corporation | 4 | $82 |
| LEO Pharma Inc. | 3 | $72 |
| Janssen Biotech, Inc. | 3 | $56 |
| Galderma Laboratories, L.P. | 2 | $30 |
Products named: SKYRIZI, DUPIXENT, Bimzelx, TALTZ, COSENTYX, RINVOQ, AYVAKIT, TREMFYA.
Industry payments across MT — which companies pay providers there.
